ONWARD Medical
Develops neurostimulation therapies intended to restore movement and improve recovery for people living with spinal cord injuries.
Overview
ONWARD Medical is a medical technology company advancing therapies for spinal cord injury, with a focus on treatments designed to improve outcomes for people affected by paralysis and related neurological impairment. Its target market includes patients, clinicians and care providers working in spinal cord injury rehabilitation and therapy. The company’s key differentiator is its specialized focus on spinal cord injury therapies rather than broader neurological indications. In April 2026, the Eindhoven-based company raised about €40.6 million through a PIPE capital increase, bringing disclosed funding to roughly €41 million across one round.
Funding History
Eindhoven’s ONWARD Medical raises €40.6 million in capital increase to advance spinal cord injury therapies
Frequently Asked Questions
- How much funding does AI Funding track for ONWARD Medical?
- AI Funding tracks €41M for ONWARD Medical across 1 funding round in this database.
- Who are ONWARD Medical's investors?
- ONWARD Medical's investors include EQT Life Sciences.
- What does ONWARD Medical do?
- ONWARD Medical is a medical technology company advancing therapies for spinal cord injury, with a focus on treatments designed to improve outcomes for people affected by paralysis and related neurological impairment. Its target market includes patients, clinicians and care providers working in spinal cord injury rehabilitation and therapy. The company’s key differentiator is its specialized focus on spinal cord injury therapies rather than broader neurological indications. In April 2026, the Eindhoven-based company raised about €40.6 million through a PIPE capital increase, bringing disclosed funding to roughly €41 million across one round.
- Where is ONWARD Medical headquartered?
- ONWARD Medical is headquartered in Eindhoven, Netherlands.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
Track 395+ AI funding rounds—investors, valuations, and deal sizes from pre-seed to IPO. Updated daily so you never miss a round.
An in-depth look at how AI-focused venture capital operates — from fund structure and deal sourcing to due diligence, portfolio management, and exit strategies in the AI era.